Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXER1 | Q8TDS5 | 6/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | PHGDH | O43175 | 6/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | PPARD | Q03181 | 3/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL287263 | 0.82 | OXER1 (0.54) | OXER1 | |
| SCHEMBL3699735 | 0.82 | OXER1 (0.54) | OXER1 | |
| SCHEMBL20014473 | 0.82 | OXER1 (0.47) | OXER1PHGDHPPARGPPARDRXFP1 | |
| SCHEMBL18113010 | 0.81 | OXER1 (0.42) | OXER1PHGDHPPARGPPARDRXFP1 | |
| SCHEMBL25778964 | 0.81 | OXER1 (0.42) | OXER1PHGDHPPARGPPARDRXFP1 | |
| SCHEMBL25777910 | 0.81 | OXER1 (0.45) | OXER1PHGDHPPARGPPARDRXFP1 | |
| SCHEMBL18113212 | 0.81 | OXER1 (0.45) | OXER1PHGDHPPARGPPARDRXFP1 | |
| SCHEMBL25777912 | 0.80 | PHGDH (0.43) | OXER1PHGDHPPARGPPARDPPARA | |
| SCHEMBL25778965 | 0.79 | OXER1 (0.44) | OXER1HTR2AHTR2CPPARGPPARD | |
| SCHEMBL18112910 | 0.79 | OXER1 (0.49) | OXER1PPARGPPARDPPARAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122942-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | FLORIDA INSTITUTE OF TECHNOLOGY | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122942-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | OXER1, PTGIR, EDNRA | OXER1 1/4885HTR2A 395/4885HTR2C 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.